|
WO2021025988A1
|
|
Dosing protocols and regimens for aminosterol treatment
|
|
WO2021025973A1
|
|
Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
|
|
WO2021025974A1
|
|
Human squalamine derivatives, related compositions comprising the same, and methods of using the same
|
|
WO2020172289A1
|
|
Deuterated forms of aminosterols and methods of using the same
|
|
US2020038418A1
|
|
Methods of treating autism spectrum disorder using aminosterol compositions
|
|
US2020155574A1
|
|
Aminosterol compositions and methods of using the same for treating schizophrenia
|
|
US2020038414A1
|
|
Methods of treating constipation using aminosterol compositions
|
|
US2020038419A1
|
|
Methods of treating multiple system atrophy using aminosterol compositions
|
|
US2020038416A1
|
|
Methods of treating cardiac conduction defects using aminosterol compositions
|
|
US2020038415A1
|
|
Aminosterol compositions and methods of using the same for treating erectile dysfunction
|
|
US2020038413A1
|
|
Methods of treating parkinson's disease using aminosterol compositions
|
|
US2020038420A1
|
|
Aminosterol compositions and methods of using the same for treating depression
|
|
US2020038417A1
|
|
Methods and compositions for treating cognitive impairment
|
|
US2020129528A1
|
|
Methods for treating blood pressure conditions using aminosterol compositions
|
|
US2020038412A1
|
|
Methods of treating alzheimer's disease using aminosterol compositions
|
|
BR112020025296A2
|
|
METHODS AND COMPOSITIONS TO TREAT AND / OR PREVENT PROGRESSION AND / OR START OF AGE-RELATED NEURODEGENERATION
|
|
WO2019190950A1
|
|
Methods and compositions for treating hallucinations and conditions related to the same
|
|
EP3704132A1
|
|
New squalamine solid forms and methods of making the same
|
